Arrowhead Pharma purchases land ahead of new manufacturing facility buildout
New campus will support the company as it approaches potential commercialisation of its rapidly progressing clinical candidates
Arrowhead Pharmaceuticals, a company specialising in harnessing RNAi technology to silence disease-causing genes, has purchased 13 acres of land in the Verona Technology Park in Verona, WI with a view to building a new 140,000-sq. ft GMP manufacturing plant.
The company also plans to build an associated laboratory and office facility, occupying approximately 115,000 sq. ft, to support process development and analytical activities.
The transaction comes at a time when, according to Arrowhead's president and CEO Christopher Anzalone, the company's investigational RNAi medicines continue to expand rapidly.
The new campus will, therefore, enable the company to advance the manufacturing process, including at commercial scale, of its TRiM-(Targeted RNAi Molecule) enabled drug candidates.
The company claims therapeutics developed with this platform offer several advantages, including simplified manufacturing and reduced costs, and multiple routes of administration.
Construction of the $200–250 million investment is expected to begin in the first quarter of 2022. Completion of the lab and office space is scheduled for the first quarter of 2023, andcompletion of the manufacturing facility is anticipated in the fourth quarter of 2023.
During this time, Arrowhead will continue to operate additional R&D facilities in Madison, WI, and San Diego, CA.
Once complete, the new facility is set to create about 250 new local jobs.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance